Epithelial cells in bone marrow of breast cancer patients at time of primary surgery:: Clinical outcome during long-term follow-up

被引:158
作者
Gebauer, G
Fehm, T
Merkle, E
Beck, EP
Lang, N
Jäger, W
机构
[1] Sidney Kimmel Canc Ctr, Dept Cell & Mol Biol, San Diego, CA 92121 USA
[2] Univ Texas, SW Med Sch, Canc Immunol Ctr, Dallas, TX 75230 USA
[3] Olgaspital, Dept Obstet & Gynecol, Stuttgart, Germany
[4] Univ Erlangen Nurnberg, Dept Obstet & Gynecol, Erlangen, Germany
关键词
D O I
10.1200/JCO.2001.19.16.3669
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the detection of epithelial cells in bone marrow of breast cancer patients as an indicator of metastatic disease. Patients and Methods: Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer patients during primary surgery. Specimens were stained immunocytochemically for epithelial cells expressing cytokeratins or the epithelial membrane antigen. The long-term outcomes of these patients were analyzed in this study. Results: In 166 of 393 patients, epithelial cells were found in bone marrow (BM) aspirates. These patients were designated BM+. The rate of tumor recurrence or cancer-related death was significantly higher in BM+ patients than in BM- patients. Multivariate analysis using the Cox regression model revealed BM status as a prognostic parameter independent of tumor size and axillary lymph node status. However, tumor size and axillary lymph node status were clearly superior prognostic parameters. Conclusion: Disseminated epithelial cells in BM are associated with poor clinical outcome in breast cancer patients. However, the presence of these cells is not a sufficient parameter to predict growing metastases in the majority of patients, suggesting that epithelial cells in the BM of breast cancer patients at the time of surgery have limited metastatic potential. The role of these cells needs to be further evaluated. J Clin Oncol 19:3669-3674. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:3669 / 3674
页数:6
相关论文
共 25 条
[1]  
Benson JR, 1999, LANCET, V354, P1998, DOI 10.1016/S0140-6736(05)76770-2
[2]  
Borgen E, 1998, J PATHOL, V185, P427, DOI 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO
[3]  
2-7
[4]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[5]  
Braun S, 1999, INT J CANCER, V84, P1, DOI 10.1002/(SICI)1097-0215(19990219)84:1<1::AID-IJC1>3.0.CO
[6]  
2-A
[7]   Prognostic significance of micrometastatic bone marrow involvement [J].
Braun, S ;
Pantel, K .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :201-216
[8]  
CECI G, 1988, CANCER, V61, P96, DOI 10.1002/1097-0142(19880101)61:1<96::AID-CNCR2820610116>3.0.CO
[9]  
2-5
[10]   PREDICTION OF EARLY RELAPSE IN PATIENTS WITH OPERABLE BREAST-CANCER BY DETECTION OF OCCULT BONE-MARROW MICROMETASTASES [J].
COTE, RJ ;
ROSEN, PP ;
LESSER, ML ;
OLD, LJ ;
OSBORNE, MP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) :1749-1756